A registry study suggests patients diagnosed with this nonatherosclerotic arterial disease after age 65 can be reassured they’ll likely fare well with medical therapy alone.
USPSTF Is Missing the Mark on the Ankle-Brachial Index in PAD Screening. Here’s Why.
The task force’s draft recommendation against using the ABI to assess for peripheral artery disease in asymptomatic adults would perpetuate underdiagnosis, argues Dr. Heather Gornik.
Pharmacomechanical Thrombolysis Does Not Protect Against Post-Thrombotic Syndrome
First-line therapy for most patients with DVT should remain anticoagulation without pharmacomechanical thrombolysis, suggests the multicenter ATTRACT trial.
CMS Decision on Exercise Therapy for PAD: A Clear Win for Patients
Cleveland Clinic vascular specialists explain why this Medicare coverage decision is a big deal and exactly how supervised exercise therapy benefits patients with peripheral artery disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Vascular Medicine in 2017: The View from SVM’s Outgoing and Incoming Presidents
The Society for Vascular Medicine’s new president joins her predecessor for a Q&A on their subspecialty’s unique challenges and opportunities, plus some thoughts on what the future might hold.
New PAD Guidelines Stress Comprehensive Care, Endorse Structured Exercise
The new AHA/ACC recommendations on peripheral artery disease (PAD) extend more broadly across the spectrum of PAD care. The guidelines’ vice chair explains why they’re more of a reboot than an update.
Two Serious and Potentially Related Diagnoses Are Often Missed in Younger Women
Fibromuscular dysplasia should be on every primary care physician’s radar because it can lead to spontaneous coronary artery dissection. Prompt referral of patients is key to successful care.
Heart & Vascular Clinical Trials
Current Cleveland Clinic heart and vascular studies include two on leadless pacemakers, one on evolocumab for statin intolerance and one on gut flora reduction after dietary intervention.
International FMD Researchers Find Common Ground
First international FMD symposium stimulated participants to identify research projects in epidemiology, registries, genetics and imaging and clinical management in order to advance understanding of this disease.